Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
School of Medicine, Meharry Medical College, Nashville, TN, USA.
Ann Surg Oncol. 2021 Oct;28(11):6551-6561. doi: 10.1245/s10434-020-09562-8. Epub 2021 Feb 14.
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy, and many prognostic factors that influence survival remain undefined. Individually, the GRAS (Grade, Resection status, Age, and Symptoms of hormone hypersecretion) parameters have demonstrated their prognostic value in ACC. This study aimed to assess the value of a cumulative GRAS score as a prognostic indicator after ACC resection.
A retrospective cohort study of adult patients who underwent surgical resection for ACC between 1993 and 2014 was performed using the United States Adrenocortical Carcinoma Group (US-ACCG) database. A sum GRAS score was calculated for each patient by adding one point each when the criteria were met for tumor grade (Weiss criteria ≥ 3 or Ki67 ≥ 20%), resection status (micro- or macroscopically positive margin), age (≥ 50 years), and preoperative symptoms of hormone hypersecretion (present). Overall survival (OS) and disease-free survival (DFS) by cumulative GRAS score were analyzed by the Kaplan-Meier method and log-rank test.
Of the 265 patients in the US-ACCG database, 243 (92%) had sufficient data available to calculate a cumulative GRAS score and were included in this analysis. The 265 patients comprised 23 patients (10%) with a GRAS of 0, 52 patients (21%) with a GRAS of 1, 92 patients (38%) with a GRAS of 2, 63 patients (26%) with a GRAS of 3, and 13 patients (5%) with a GRAS of 4. An increasing GRAS score was associated with shortened OS (p < 0.01) and DFS (p < 0.01) after index resection.
In this retrospective analysis, the cumulative GRAS score effectively stratified OS and DFS after index resection for ACC. Further prospective analysis is required to validate the cumulative GRAS score as a prognostic indicator for clinical use.
肾上腺皮质癌(ACC)是一种罕见但具有侵袭性的恶性肿瘤,许多影响生存的预后因素仍未确定。单独来看,GRAS(分级、切除状态、年龄和激素过度分泌的症状)参数已经证明了其在 ACC 中的预后价值。本研究旨在评估累积 GRAS 评分作为 ACC 切除后预后指标的价值。
对 1993 年至 2014 年间在美国肾上腺皮质癌协作组(US-ACCG)数据库中接受手术切除的成人患者进行回顾性队列研究。通过为每个患者的肿瘤分级(Weiss 标准≥3 或 Ki67≥20%)、切除状态(显微镜或肉眼阳性边缘)、年龄(≥50 岁)和术前激素过度分泌的症状(存在)满足标准时分别加 1 分,计算每个患者的累积 GRAS 评分。通过 Kaplan-Meier 方法和对数秩检验分析累积 GRAS 评分的总生存率(OS)和无病生存率(DFS)。
在 US-ACCG 数据库的 265 例患者中,有 243 例(92%)有足够的数据可用于计算累积 GRAS 评分,并纳入本分析。265 例患者中,0 分 23 例(10%),1 分 52 例(21%),2 分 92 例(38%),3 分 63 例(26%),4 分 13 例(5%)。随着 GRAS 评分的增加,指数切除后 OS(p<0.01)和 DFS(p<0.01)缩短。
在这项回顾性分析中,累积 GRAS 评分有效地对 ACC 指数切除后的 OS 和 DFS 进行分层。需要进一步的前瞻性分析来验证累积 GRAS 评分作为临床应用的预后指标。